Company

Theraclone Sciences

Theraclone Sciences discovers and develops human monoclonal antibodies for infectious diseases and cancer.

About

Founded in 2004 and based in Seattle, US, Theraclone Sciences develops human monoclonal antibodies using screening technology. The company has licensed HIV antibodies to Gilead and partnered with OncoResponse to apply its platform in oncology. In May 2015, it raised USD 3.08 mn in Series C funding led by ARCH Venture Partners, Canaan Partners, and HealthCare Ventures.

7Funding rounds

9Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in